Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Swiss pharmaceutical giant Novartis reported another solid quarter on Tuesday, raising its guidance for the third time this year. Yet its shares were the worst performers among big pharma ...

BASEL, Switzerland (AP) — BASEL, Switzerland (AP) — Novartis AG (NVS) on Tuesday reported third-quarter earnings of $3.19 billion. On a per-share basis, the Basel, Switzerland-based company ...

Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...

Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

A year after spinning off its generics business to become a "pure-player" developer of innovative medicines, Novartis registered a 15 percent increase in its core net profit to $4.1 billion during ...

ZURICH (Reuters) - Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant ...

Novartis forecasts full-year sales growth in ... With the momentum in our business and pipeline, we were able to once again upgrade our full-year guidance and remain highly confident in our ...